Table 1.

Patient characteristics

	All (n = 32)	Non-transplanted patients (n = 22)	Renal transplant recipients (n = 10)
Sex
Male % (n)	40.6 (13)	40.9 (9)	40.0 (4)
Age
at first ravulizumab infusion in years (range)	41.4 (19–78)	42.9 (19–78)	38.1 (20–72)
at first occurrence of aHUS in years (range)	34.5 (3–73)	38.6 (3–73)	24.2 (6–42)a
Comorbidities % (n)
0	21.9 (7)	27.3 (6)	10.0 (1)
1	18.8 (6)	22.7 (5)	10.0 (1)
2	9.4 (3)	4.5 (1)	20.0 (2)
3	18.8 (6)	18.2 (4)	20.0 (2)
> 3	31.2 (10)	27.3 (6)	40.0 (4)
Duration of eculizumab treatment in months (range)	28.7 (3–120)	30.9 (3–120)	22.9 (3–51)b
Patients with ≥ 1 pathogenic genetic variant % (n)	71.9 (23)	77.3 (17)	60.0 (6)
Time since complement mutation analysis
≥ 1 pathogenic genetic variant; years (range)	5.7 (0–15)	4.6 (0–11)	8.8 (2–15)
no pathogenic genetic variant; years (range)	5.6 (1–12)	4.5 (1–8)	6.8 (1–12)

^aData missing for one patient with a highly positive family history and diagnosis > 10 years ago

^bFor two renal transplant recipients, duration of eculizumab was not known